Adaptin Bio (APTN) Enterprise Value (2022 - 2026)

Adaptin Bio has disclosed Enterprise Value across 5 years of filings, most recently posting -$301309.0 for Q1 2026.

• Quarterly Enterprise Value rose 87.31% year-over-year to -$301309.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$301309.0 (up 87.31% YoY) and the FY2025 annual result came in at -$459174.0, down 1247.14% from the prior year.
• Enterprise Value grew to -$301309.0 in Q1 2026, from -$459174.0 in the prior quarter.
• Across five years, Enterprise Value topped out at -$322.0 in Q3 2024 and bottomed at -$2.4 million in Q1 2025.
• The 5-year median for Enterprise Value is -$23776.0 (2024), against an average of -$394976.6.
• Year-over-year, Enterprise Value slumped 179741.3% in 2025 and soared 87.31% in 2026.
• Adaptin Bio's Enterprise Value stood at -$500.0 in 2022, then slumped by 850.8% to -$4754.0 in 2023, then tumbled by 616.98% to -$34085.0 in 2024, then plunged by 1247.14% to -$459174.0 in 2025, then jumped by 34.38% to -$301309.0 in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$301309.0, -$459174.0, and -$579089.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.